Cerenome, Inc.
Plus Therapeutics, Inc. is a healthcare company developing and commercializing precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its CNSide Diagnostics subsidiary offers the CNSide cerebrospinal-fluid tumor cell enumeration test, a laboratory-developed test for detecting and… From the company’s description.
Over the twelve months to Jun 30, 2026, Cerenome, Inc. reported revenue of $4.20M, down 21.0% from a year earlier, and a net loss of $26.09M. Its operating margin was −628.1%, and operations used $22.18M in cash. In fiscal 2025, it reported revenue of $5.21M, down 10.5% from fiscal 2024, and a net loss of $22.39M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cerenome, Inc. does
In the company’s own words
Plus Therapeutics, Inc. is a healthcare company developing and commercializing precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its CNSide Diagnostics subsidiary offers the CNSide cerebrospinal-fluid tumor cell enumeration test, a laboratory-developed test for detecting and characterizing cancer cells that have spread to the central nervous system; patients with leptomeningeal metastases and their treating healthcare providers are its intended users. The company’s lead investigational therapy, rhenium (186Re) obisbemeda, is designed for localized delivery to recurrent glioblastoma, leptomeningeal metastases and pediatric brain cancers. Its preclinical 188RNL-BAM program is being developed for intra-arterial radiation delivery to solid tumors, initially liver cancer. The business therefore spans diagnostics and radiotherapeutics, with no segment revenue breakdown stated here. The CNSide test returned to commercial use in 2025, and national agreements with UnitedHealthcare and Humana broaden access. The company acquired the licensed nanoliposome radiotherapeutic portfolio from NanoTx in 2020 and acquired the CNSide platform in 2024. Its website is www.plustherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- HOUSTON, TX
- Fiscal year end
- December
- CIK
- 1095981
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cerenome, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cerenome, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cerenome, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cerenome, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cerenome, Inc.'s last four quarterly filings that the numbers alone won't show?”